Abstract:Seho Kweon, 1, 2 Seong Jin Park, 3 Ha Kyeong Lee, 1 Seo Hee Kang, 4 Kwan-Young Chang, 4 Jeong Uk Choi, 5 Jooho Park, 6 Jung-Hyun Shim, 7 Jin Woo Park, 7 Youngro Byun 1, 3 1 Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea; 2 College of Pharmacy, Chonnam National University, Gwangju, 61186, Republic of Korea; 3 College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea; 4 Global R&D Center, IcureBNP, Seoul, 06170, Republic of Korea; 5 College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea; 6 Department of Biomedical & Health Science, Konkuk University, Chungju, 27478, Republic of Korea; 7 College of Pharmacy and Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam, 58554, Republic of Korea Correspondence: Jin Woo Park; Youngro Byun, Tel +82 61 450 2704, Email ; Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic. However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability and gastrointestinal (GI) stability. Methods: To mitigate such limitations, an oral nanoformulation of liraglutide (LG) was designed and achieved by combining LG with bile acid derivatives using the nanoprecipitation method. This strategy allowed the bile acid moieties to localize at the nanoparticle surface, enhancing the binding affinity for apical sodium-dependent bile acid transporter (ASBT) and improving GI stability. The in vitro characteristics, cellular permeability, and absorption mechanisms of the LG nanoformulation (LG/TD-NF) were thoroughly investigated. Furthermore, the in vivo oral absorption in rats and the glucose-lowering effects in a diabetic ( db/db ) mouse model were evaluated. Results: The LG/TD-NF produced neutral nanoparticles with a diameter of 58.7 ± 4.3 nm and a zeta potential of 4.9 ± 0.4 mV. Notably, when exposed to simulated gastric fluid, 65.7 ± 3.6% of the LG/TD-NF remained stable over 120 min, while free LG was fully degraded. Relative to unformulated LG, the Caco-2 cellular permeability of the nanoformulation improved, measuring 10.9 ± 2.1 (× 10 − 6 cm/s). The absorption mechanism prominently featured endocytosis simultaneously mediated by both ASBT and epidermal growth factor receptor (EGFR). The oral bioavailability of the LG/TD-NF was determined to be 3.62% at a dosage of 10 mg/kg, which is 45.3 times greater than that of free LG. In a diabetes model, LG/TD-NF at 10 mg/kg/day exhibited commendable glucose sensitivity and reduced HbA1c levels by 4.13% within 28 days, similar to that of subcutaneously administered LG at a dosage of 0.1 mg/kg/day. Conclusion: The oral LG/TD-NF promotes ASBT/EGFR-mediated transcytosis and assures cellular permeability within the GI tract. This method holds promise for the development of oral GLP-1A peptides as an alternative to injections, potentially enhancing patient adherence to maintenance therapy. Keywords: nanoformulation of GLP-1A, oral liraglutide, ASBT-mediated endocytosis, EGFR Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by inadequate insulin production, and in some instances, a decline in insulin sensitivity as the condition progresses. 1 Orally administered pharmacological agents, such as metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors, are extensively utilized as potential therapeutic interventions for T2DM management in the context of long-term treatment. Moreover, injectable therapeutic peptides, including glucagon-like peptide-1 agonist (GLP-1A) and insulin, often serve as primary treatment modalities. 2,3 Due to their superior glucose-lowering effects and reduced cardiovascular risks compared to chemical-based medications, these therapeutic peptides have garnered significant attention in drug development. Thus, there is an intensified focus on advancing synthesis and purification technologies to further the development of these peptides. 4 However, the need for prolonged and frequent invasive administration can lead to decreased patient compliance and heightened risk for infections, potentially resulting in treatment failure. Several modified forms of GLP-1A have been introduced to mitigate these limitations. Some of these have extended half-lives, such as liraglutide (LG), lixisenatide, albiglu -Abstract Truncated-

Formulation of Deformable Liponiosomal Hybrid of Repaglinide: In vitro Characterization and Evaluation of the Anti-Diabetic Effect

Preparation of nanoparticle and nanoemulsion formulations containing repaglinide and determination of pharmacokinetic parameters in rats

Preparation and Evaluation of Repaglinide Loaded Liposomes by Ether Injection Method

Repaglinide-Solid Lipid Nanoparticles in Chitosan Patches for Transdermal Application: Box-Behnken Design, Characterization, and In Vivo Evaluation

Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition

Nanosuspension-Based Repaglinide Fast-Dissolving Buccal Film for Dissolution Enhancement

Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo

Transdermal Drug Delivery System of Linagliptin Sustained-release Microparticle Gels: In vitro Characterization and In vivo Evaluation

Design and biological evaluation of Repaglinide loaded polymeric nanocarriers for diabetes linked neurodegenerative disorder: QbD-driven optimization, in situ, in vitro and in vivo investigation

Injectable and Thermosensitive Hydrogel Containing Liraglutide As a Long-Acting Antidiabetic System

Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin

Development, in vitro and in vivo evaluation of β-cyclodextrin/Polyvinyl alcohol-co-poly (2-acrylamide-2-methylpropane sulfonic acid) cross-linked hybrid IPN-nanogels to improve the dissolution and absorption of anti-hyperlipidemic drug

Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and Probiotic: Optimization and In-vitro Characterization

[Study on Preparation and Oral Efficacy of Insulin-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles].

Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance

Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract

Controlled release of liraglutide using thermogelling polymers in treatment of diabetes

Investigation of Alogliptin-Loaded In Situ Gel Implants by 23 Factorial Design with Glycemic Assessment in Rats

Polymeric Nano-Vesicles Via Intermolecular Action to Load and Orally Deliver Insulin with Enhanced Hypoglycemic Effect

Liposomes Containing Glycocholate As Potential Oral Insulin Delivery Systems: Preparation, in Vitro Characterization, and Improved Protection Against Enzymatic Degradation

Optimization of Potential Nanoemulgels for Boosting Transdermal Glimepiride Delivery and Upgrading Its Anti-Diabetic Activity